The standard treatment of Crohn’s disease (Crohn’s disease) is based on the “step-up” strategy. However, results from the PROFILE study indicate that in newly diagnosed Crohn’s disease, early use of a TNF-α inhibitor in combination with an immunomodulator is significantly more effective than stepwise escalation. The recently published results of several years of follow-up show that this also applies to the longer-term outcomes. As interesting as these study results are, in terms of a “best practice” approach, the guideline advises that the respective course of treatment should be assessed individually using surrogate parameters and adjusted accordingly depending on the response.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)